ASX - By Stock
|
PIQ |
Re:
Ann: Update on commercialisation of PromarkerD in the USA
|
|
The Rad
|
42 |
19K |
1 |
11/09/24 |
11/09/24 |
ASX - By Stock
|
42
|
19K
|
1
|
|
ASX - By Stock
|
PCL |
Re:
General Thoughts
|
|
The Rad
|
5.6K |
2.7M |
19 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
5.6K
|
2.7M
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Application for quotation of securities - DXB
|
|
The Rad
|
153 |
38K |
10 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
153
|
38K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of cessation of securities - DXB
|
|
The Rad
|
9 |
2.8K |
6 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
9
|
2.8K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD US reimbursement price & Aus regulatory decision
|
|
The Rad
|
17 |
7.9K |
11 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
17
|
7.9K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
The Rad
|
5 |
2.1K |
6 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
5
|
2.1K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Letter of intent with Sonic Healthcare USA extended
|
|
The Rad
|
24 |
8.9K |
7 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
24
|
8.9K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options
|
|
The Rad
|
9 |
4.6K |
8 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
9
|
4.6K
|
8
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD manufacturing tech-transfer completed
|
|
The Rad
|
3 |
1.7K |
13 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
3
|
1.7K
|
13
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: FDA advises regulatory pathway for PromarkerD in US
|
|
The Rad
|
50 |
16K |
31 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
50
|
16K
|
31
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Modelling shows PromarkerD could save US payers $384 billion
|
|
The Rad
|
10 |
3.9K |
8 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
10
|
3.9K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Lapse of Unlisted Options
|
|
The Rad
|
1 |
1.0K |
8 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
1
|
1.0K
|
8
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
The Rad
|
322 |
96K |
5 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
322
|
96K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
strain results
|
|
The Rad
|
32 |
7.7K |
3 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
32
|
7.7K
|
3
|
|
ASX - By Stock
|
ISD |
Re:
Ann: Change in substantial holding
|
|
The Rad
|
5 |
2.7K |
0 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
5
|
2.7K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: AGM Investor Presentation
|
|
The Rad
|
22 |
5.9K |
10 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
22
|
5.9K
|
10
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
The Rad
|
18 |
4.8K |
3 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
18
|
4.8K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
The Rad
|
18 |
4.8K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
18
|
4.8K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
The Rad
|
627 |
265K |
11 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
The Rad
|
627 |
265K |
30 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
30
|
|
ASX - By Stock
|
DXB |
Re:
General Discussion
|
|
The Rad
|
134 |
39K |
2 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
134
|
39K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
General Discussion
|
|
The Rad
|
134 |
39K |
7 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
134
|
39K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
The Rad
|
22 |
9.4K |
12 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
22
|
9.4K
|
12
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD Intellectual Property portfolio expands
|
|
The Rad
|
54 |
17K |
8 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
54
|
17K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
The Rad
|
218 |
58K |
8 |
20/07/20 |
20/07/20 |
ASX - By Stock
|
218
|
58K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
The Rad
|
218 |
58K |
1 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
218
|
58K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Appendix 2A - Exercise of Employee Options
|
|
The Rad
|
8 |
2.0K |
3 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
8
|
2.0K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Global REMAP-CAP Platform Trial Protocol To Include DMX-200
|
|
The Rad
|
247 |
79K |
11 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
247
|
79K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Global REMAP-CAP Platform Trial Protocol To Include DMX-200
|
|
The Rad
|
247 |
79K |
4 |
11/06/20 |
11/06/20 |
ASX - By Stock
|
247
|
79K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International receives COVID-19 research grants
|
|
The Rad
|
23 |
7.8K |
6 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
23
|
7.8K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Appendix 3G - Issue of Employee Options
|
|
The Rad
|
4 |
1.9K |
4 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
4
|
1.9K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International expands study with US big pharma
|
|
The Rad
|
16 |
5.2K |
3 |
07/04/20 |
07/04/20 |
ASX - By Stock
|
16
|
5.2K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International expands study with US big pharma
|
|
The Rad
|
16 |
5.2K |
10 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
16
|
5.2K
|
10
|
|
ASX - By Stock
|
PIQ |
Re:
New News
|
|
The Rad
|
93 |
653K |
6 |
16/03/20 |
16/03/20 |
ASX - By Stock
|
93
|
653K
|
6
|
|
ASX - By Stock
|
CGF |
Re:
Ann: Update - Dividend/Distribution - CGF
|
|
The Rad
|
3 |
1.3K |
1 |
13/03/20 |
13/03/20 |
ASX - By Stock
|
3
|
1.3K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
The Rad
|
7 |
15K |
5 |
26/02/20 |
26/02/20 |
ASX - By Stock
|
7
|
15K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics raises $3m in heavily oversubscribed Placement
|
|
The Rad
|
29 |
16K |
4 |
15/11/19 |
15/11/19 |
ASX - By Stock
|
29
|
16K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics receives $1.1 million in R&D tax incentive
|
|
The Rad
|
27 |
8.2K |
9 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
27
|
8.2K
|
9
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Appendix 3B - Exercise of Employee Options
|
|
The Rad
|
4 |
3.0K |
6 |
04/11/19 |
04/11/19 |
ASX - By Stock
|
4
|
3.0K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Where to from here?
|
|
The Rad
|
55 |
17K |
15 |
23/09/19 |
23/09/19 |
ASX - By Stock
|
55
|
17K
|
15
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Annual Report to shareholders
|
|
The Rad
|
9 |
6.2K |
5 |
05/09/19 |
05/09/19 |
ASX - By Stock
|
9
|
6.2K
|
5
|
|
ASX - By Stock
|
WSA |
Re:
Ann: Full Year Financial Results Presentation
|
|
The Rad
|
130 |
54K |
3 |
23/08/19 |
23/08/19 |
ASX - By Stock
|
130
|
54K
|
3
|
|
ASX - By Stock
|
WSA |
Re:
Ann: Full Year Financial Results Presentation
|
|
The Rad
|
130 |
54K |
0 |
23/08/19 |
23/08/19 |
ASX - By Stock
|
130
|
54K
|
0
|
|
ASX - By Stock
|
WSA |
Re:
Ann: Full Year Financial Results Presentation
|
|
The Rad
|
130 |
54K |
0 |
23/08/19 |
23/08/19 |
ASX - By Stock
|
130
|
54K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
News overdue
|
|
The Rad
|
32 |
8.6K |
7 |
06/07/19 |
06/07/19 |
ASX - By Stock
|
32
|
8.6K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
News overdue
|
|
The Rad
|
32 |
8.6K |
7 |
05/07/19 |
05/07/19 |
ASX - By Stock
|
32
|
8.6K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
News overdue
|
|
The Rad
|
32 |
8.6K |
11 |
30/06/19 |
30/06/19 |
ASX - By Stock
|
32
|
8.6K
|
11
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Exercise of Options - Secondary Trading Notice & Appendix 3B
|
|
The Rad
|
1 |
1.2K |
4 |
26/06/19 |
26/06/19 |
ASX - By Stock
|
1
|
1.2K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Austrade support for PromarkerD
|
|
The Rad
|
30 |
10K |
7 |
15/04/19 |
15/04/19 |
ASX - By Stock
|
30
|
10K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Austrade support for PromarkerD
|
|
The Rad
|
30 |
10K |
4 |
15/04/19 |
15/04/19 |
ASX - By Stock
|
30
|
10K
|
4
|
|